{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:51:39Z","timestamp":1787241099767,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40262-025-01484-6","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:45:55Z","timestamp":1743313555000},"page":"611-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment"],"prefix":"10.1007","volume":"64","author":[{"given":"Maulik","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya R.","family":"Siddani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Erfan","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-6062","authenticated-orcid":false,"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"7042","key":"1484_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677\u201381.","journal-title":"Nature"},{"issue":"12","key":"1484_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149\u201359.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1484_CR3","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.21.02188","volume":"40","author":"CN Harrison","year":"2022","unstructured":"Harrison CN, Garcia JS, Somervaille TCP, et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy. J Clin Oncol. 2022;40(15):1671\u201380.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1484_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","volume":"5","author":"M Waibel","year":"2013","unstructured":"Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5(4):1047\u201359.","journal-title":"Cell Rep"},{"issue":"3","key":"1484_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114363","volume":"10","author":"J Guo","year":"2015","unstructured":"Guo J, Roberts L, Chen Z, Merta PJ, Glaser KB, Shah OJ. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. PLoS\u00a0One. 2015;10(3): e0114363.","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"1484_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/jcpt.12193","volume":"39","author":"J Yang","year":"2014","unstructured":"Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer. J Clin Pharm Ther. 2014;39(6):680\u20134.","journal-title":"J Clin Pharm Ther"},{"key":"1484_CR7","unstructured":"Serby M, Ahmed T, Yang J, Xiong H, Lee A, Shen J. Metabolism and disposition of ABT-263 in humans. Presented at: Great Lakes Drug Metabolism Discussion Group Annual Meeting; May 9\u201310, 2013; Toledo."},{"issue":"4","key":"1484_CR8","first-page":"2001","volume":"34","author":"AH Salem","year":"2014","unstructured":"Salem AH, Yang J, Grahamr A, et al. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients. Anticancer Res. 2014;34(4):2001\u20136.","journal-title":"Anticancer Res"},{"issue":"9","key":"1484_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/jcph.128","volume":"53","author":"Y Chang","year":"2013","unstructured":"Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J Clin Pharmacol. 2013;53(9):962\u20136.","journal-title":"J Clin Pharmacol"},{"key":"1484_CR10","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 11 Feb 2025."},{"issue":"4","key":"1484_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1124\/dmd.106.012294","volume":"35","author":"JC Kalvass","year":"2007","unstructured":"Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos. 2007;35(4):660\u20136.","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01484-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:24:56Z","timestamp":1745925896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01484-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"27 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, writing, reviewing, and approving the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.P., J.P., D.M.H., S.R.S., K.C.M., E.J.K., M.E.U., R.M.M., and A.R.P. are AbbVie employees and may hold AbbVie stocks or options. J.C.R. has no conflicts of interest to declare. T.M. is an employee and equity owner of Orlando Clinical Research Center. E.L. is a researcher for 89Bio Inc., AbbVie Inc., Akero Therapeutics, Alnylam Pharmaceuticals Inc., Amgen, Astrazeneca, Axcella Health, Boehringer Ingelheim, Bristol-Myers Squibb, Cymabay Therapeutics, DSM, Eli Lilly and Company, Enanta Pharmaceuticals, Enyo Pharma, Exalenz Bioscience, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Genentech, Gilead Sciences, GlaxoSmithKline, Hanmi Pharmaceuticals, Hightide Biopharma, Intercept Pharmaceuticals, Inventiva, Janssen Pharmaceuticals, Madrigal Pharmaceuticals, Merck & Co., NGM Biopharmaceuticals Inc., Northsea Therapeutics, Novartis, Novo Nordisk Inc., Pfizer, Poxel Co., Roche, Sagimet Biosciences, Takeda, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Pharmaceuticals; reports advisory board for Akero, Boehringer Ingelheim, BMS, Intercept, Novo Nordisk, Sagimet, and Terns; and speaker for AbbVie, Gilead Sciences, and Intercept.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the protocol, and in accordance with Good Clinical Practice guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocol was approved by three institutional review boards: (a) Orlando Clinical Research Center, Orlando, FL (TESLA 222707 approved on 3 December 2020), (b) Clinical Pharmacology of Miami, Miami, FL (TESLA 222709 approved on 20 November 2020), and (c) Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX (TESLA 222740 approved on 20 September 2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for the publication of study reports or scientific presentations was obtained from the patients.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      , then select \u201cHome.\u201d","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.E.U., M.P., and A.R.P. wrote the manuscript. M.P., J.P., D.M.H., S.R.S., R.M.M., and A.R.P. designed the study. T.M., E.L., and J.C.R. collected the clinical data. M.E.U. and E.J.K. performed the data analysis. M.E.U., M.P., A.R.P., R.M.M., D.M.H., and S.R.S. interpreted the results. All authors participated in the critical review, revision of this manuscript, and provided approval of the manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}